Our Therapeutics

Veterinarians are at the heart of maintaining pet health. Pets are in the heart and soul of their owners.

Pet owners look to their veterinarian for the best recommendations when needing to treat a sick pet that they love. Whether it’s treating osteoarthritis pain, stimulating appetite or providing post-operative pain relief, veterinarians want to be at the forefront of medical innovation and have access to novel tools.

That’s why Aratana is committed to providing innovative therapeutics to help veterinarians raise the standard of care in veterinary medicine. We too believe pets are family, and they deserve high quality medical care.

The Aratana approach to pet therapeutics is built around bringing the best in scientific advances from human science to veterinary medicine and our pets. Take a look at our exciting portfolio of FDA-approved therapeutics.

 

ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs.

ENTYCE is a selective ghrelin receptor agonist that mimics ghrelin, the naturally-occurring “hunger hormone,” to stimulate appetite in dogs. ENTYCE is a flavored, liquid product administered orally once daily.

> Learn more about ENTYCE

NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs.

NOCITA is a long-acting, local anesthetic that provides up to 72 hours post-operative pain relief by releasing bupivacaine over time from multi-vesicular liposomes. The therapeutic is administered as a single dose by tissue infiltration injection during surgical closure following cranial cruciate ligament surgery in dogs.

> Learn more about NOCITA

GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs.

Galliprant is a first-in-class piprant and a non-COX-inhibiting prostaglandin receptor antagonist (PRA). It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation, and does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.¹

> In co-promotion with Elanco. Learn more at galliprantfordogs.com/vet

BLONTRESS® as an aid in the treatment of dogs with B-cell lymphoma and TACTRESS® as an aid in the treatment of dogs with T-cell lymphoma. 

BLONTRESS AND TACTRESS are two canine-specific monoclonal antibody (MAb) therapies fully licensed by the U.S. Department of Agriculture to aid in the treatment of lymphoma.

IMPORTANT SAFETY INFORMATION

GALLIPRANT® (grapiprant tablets) Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see full product label or call 1-888-545-5973 for full prescribing information.

ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency.  Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

USCACGLP00049

1. Kirkby Shaw, K., Rausch-Derra, L., and Rhodes, L. 2016. “Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation.” Vet. Med. Sci. 2: 3-9.

Related News Posts